This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

In-Depth Analysis on the Latest Policy and Reform Initiatives Impacting Pricing, Quality and Transparency

A meeting that goes beyond theory and policy to equip stakeholders with practical approaches during a time of uncertainty and the potential for seismic change.

What to Expect


In‑Depth Discussions on High‑Impact Issues
In‑Depth Discussions on High‑Impact Issues
  • Policy trends and reform initiatives
  • International Pricing Index Model (IPI) and the Most Favored-Nations Clause
  • Part D drug spending and PBM utilization management
  • Reimbursement and value-based payment initiatives
Pricing and Contracting for Manufacturers
Pricing and Contracting for Manufacturers
  • Biosimilar policy evolution and access strategy
  • Developments and updates in step therapy
  • Impact of international price benchmarks
  • Value-based contracting and outcomes arrangements as a driver for quality and innovation
Part D Strategies for Health Plans and PBMs
Part D Strategies for Health Plans and PBMs
  • Preparing for the 2021 Medicare Advantage and Part D landscape
  • Opportunities and challenges of the current regulatory landscape
  • Trends in Medicare Advantage and Part D
  • Innovative approaches to social determinants of health (SDOH)

Who Should Attend

You will benefit from attending this event if you work within the pharmaceutical, biotech or device industry with responsibilities or involvement in the following areas:


Bio/Pharma Manufacturers:
Bio/Pharma Manufacturers:


  • Public Policy
  • Government / Federal Affairs
  • Medicare
  • National / Corporate Accounts
  • Reimbursement
  • Pricing
Health Plans and PBMs:
Health Plans and PBMs:


  • Managed Markets
  • Medical Affairs
  • Medicare
  • Actuaries
  • Contracts

This conference will also benefit Law Firms, Health Policy Consultants, Medicare/Medicaid/Reimbursement consultants and software vendors providing services to the above audience.


October 2019

Forbes

Prescription drug price controls are gaining momentum nationally and also at the state level. Nationally, lowering drug prices using government levers is an area in which there appears to be at least some degree of bipartisan agreement.